Advertisement
Canada markets close in 3 minutes

  • S&P/TSX

    21,968.94
    +83.56 (+0.38%)
     

  • S&P 500

    5,100.23
    +51.81 (+1.03%)
     

  • DOW

    38,240.23
    +154.43 (+0.41%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.65
    +0.08 (+0.10%)
     

  • Bitcoin CAD

    87,272.34
    -1,032.99 (-1.17%)
     

  • CMC Crypto 200

    1,330.24
    -66.30 (-4.57%)
     

  • GOLD FUTURES

    2,350.30
    +7.80 (+0.33%)
     

  • RUSSELL 2000

    2,001.70
    +20.59 (+1.04%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.12
    +315.36 (+2.02%)
     

  • VOLATILITY

    14.96
    -0.41 (-2.67%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT RESULTS

Chevron, Exxon under pressure as falling natural gas prices hit earnings

JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug

Sarah Collins
Updated
JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug

On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.

Continue reading